Edition:
United States

Regulus Therapeutics Inc (RGLS.OQ)

RGLS.OQ on NASDAQ Stock Exchange Global Market

0.69USD
4:00pm EDT
Change (% chg)

$-0.01 (-1.44%)
Prev Close
$0.70
Open
$0.69
Day's High
$0.70
Day's Low
$0.67
Volume
16,735
Avg. Vol
60,495
52-wk High
$1.52
52-wk Low
$0.62

Chart for

About

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $72.52
Shares Outstanding(Mil.): 104.32
Dividend: --
Yield (%): --

Financials

  RGLS.OQ Industry Sector
P/E (TTM): -- 244.89 34.04
EPS (TTM): -0.53 -- --
ROI: -62.85 -5.30 13.11
ROE: -102.79 -6.83 15.11

BRIEF-Regulus Reports Q1 Loss Per Share $0.15

* REGULUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PIPELINE PROGRESS

May 10 2018

BRIEF-Kathryn Collier Joins Regulus Board Of Directors

* KATHRYN J. COLLIER JOINS REGULUS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Apr 17 2018

BRIEF-Regulus Qtrly Net Loss Per Share $0.14

* REGULUS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PIPELINE UPDATE

Mar 07 2018

BRIEF-Regulus Therapeutics Files For Mixed Shelf Of Up To $150 Mln

* REGULUS THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING‍​ Source text: (http://bit.ly/2rQDgcO) Further company coverage:

Jan 29 2018

Competitors

Earnings vs. Estimates